Ofichem, a Netherlands-based CDMO, acquired Meribel Pharma Solutions’ site in Uppsala, Sweden, to support early-phase, IP-driven drug substance development and to expand its non-GMP capabilities in the small-molecule space.
The Uppsala site, formerly part of Recipharm and known as OT Chemistry, specializes in small-scale, early-phase development work. The expertise at the facility spans traditional small molecule and emerging modalities such as antibody-drug conjugates (ADCs), oligonucleotides, and proteolysis-targeting chimeras (PROTACs), expanding Ofichem’s non-GMP capabilities in early-stage development, according to Weite H. Oldenziel, PhD, PharmD, CEO and owner of Ofichem.
“This acquisition is a strategic building block in Ofichem’s broader transformation,” said Oldenziel. “Our goal is to serve innovative biotech companies with agile, early-stage development solutions, and this site offers precisely the expertise and technologies we need to deliver on that vision.”
The acquisition reflects Ofichem’s evolving focus, building on its strong foundation serving generics and mid-sized pharma to now invest more deeply in services for biotech innovators, he continued.
The site will operate in coordination with Ofichem’s GMP manufacturing operations in Ter Apel, the Netherlands, creating a seamless path from early-stage research to commercial production, pointed out Oldenziel, adding that the acquisition also provides access to a portfolio of more than 40 biotech and mid-sized pharma clients, expanding Ofichem’s reach across the Nordic countries.
“Strategically, the partnership enables Meribel to sharpen its focus on advancing our drug product solutions, an area where we see increasing demand and opportunity,” said Bruce Vielle, CEO of Meribel. “Importantly, we remain committed to ensuring continuity and support for our customers throughout this transition and beyond. We’re confident this collaboration will deliver long-term value for everyone involved.”
The post Ofichem Acquires Meribel Pharma Solutions’ Uppsala Site appeared first on GEN – Genetic Engineering and Biotechnology News.
